健世科技－Ｂ(09877.HK) 公布，近 期，LuX-Valve Plus经血管三尖瓣介入置换(TTVR)系统的全球多中心临床试验30天临床随访结果以及JensClip经血管二尖瓣修复(TMVr)系统一年期随访结果于法国巴黎举办的EuroPCR 2025上 正 式 发 布。
TRINITY结果显示器械成功率约为97%，展现LuX-Valve Plus良好的安全性和疗效表现，患者生活质量持续改善，安全性事件发生率处于较低水平。JensClip结果显示器械操作成功率约95%。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.